stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Revenue
Alnylam Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $3.7B, up 65.2% from $2.2B in fiscal 2024. Over the twelve months to 30 September 2026 it was $5.0B. Over the past ten years it has ranged from $41.1M (fiscal 2015) to $3.7B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. Alnylam Pharmaceuticals, Inc. ranks 6th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.7B | 65.19% |
| FY2024 | $2.2B | 22.97% |
| FY2023 | $1.8B | 76.23% |
| FY2022 | $1.0B | 22.88% |
| FY2021 | $844.3M | 71.31% |
| FY2020 | $492.9M | 124.28% |
| FY2019 | $219.8M | 193.36% |
| FY2018 | $74.9M | (16.69%) |
| FY2017 | $89.9M | 90.66% |
| FY2016 | $47.2M | 14.75% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.5B | 12.95% |
| Jun 2026 | $1.3B | 10.60% |
| Mar 2026 | $1.2B | 6.39% |
| Dec 2025 | $1.1B | (12.17%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| INCY Incyte Corporation compare | $6.0B |
| ALNY Alnylam Pharmaceuticals, Inc. | $5.0B |
| JAZZ Jazz Pharmaceuticals PLC compare | $4.7B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| EXEL Exelixis, Inc. compare | $2.5B |
| INSM Insmed, Inc. compare | $1.5B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ALNY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement